Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,708.60
Bid: 1,708.40
Ask: 1,708.80
Change: 3.40 (0.20%)
Spread: 0.40 (0.023%)
Open: 1,701.60
High: 1,713.00
Low: 1,699.40
Prev. Close: 1,705.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: Peel Hunt Initiates Whitbread With Buy

Mon, 04th Nov 2019 09:10

(Alliance News) - The following London-listed shares received analyst recommendations on Monday morning and Friday afternoon:

----------

FTSE 100

----------

PEEL HUNT INITIATES WHITBREAD WITH 'BUY' - TARGET 4800 PENCE

----------

UBS CUTS SAGE GROUP PRICE TARGET TO 620 (625) PENCE - 'SELL'

----------

UBS RAISES STANDARD CHARTERED PRICE TARGET TO 690 (650) PENCE - 'NEUTRAL'

----------

UBS CUTS LLOYDS PRICE TARGET TO 62 (65) PENCE - 'BUY'

----------

JPMORGAN CUTS LLOYDS PRICE TARGET TO 68 (72) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS SMITH & NEPHEW PRICE TARGET TO 1711 (1814) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS EVRAZ PRICE TARGET TO 375 (400) PENCE - 'UNDERWEIGHT'

----------

LIBERUM RAISES GLAXOSMITHKLINE PRICE TARGET TO 1890 (1510) PENCE - 'HOLD'

----------

DEUTSCHE BANK CUTS VODAFONE PRICE TARGET TO 240 (250) PENCE - 'BUY'

----------

DEUTSCHE BANK CUTS RSA INSURANCE PRICE TARGET TO 560 (565) PENCE - 'HOLD'

----------

DEUTSCHE BANK RAISES INTERNATIONAL CONSOLIDATED AIRLINES PRICE TARGET TO 670 (630) PENCE - 'BUY'

----------

GOLDMAN CUTS EXPERIAN PRICE TARGET TO 2500 (2600) PENCE - 'NEUTRAL'

----------

JEFFERIES CUTS IMPERIAL BRANDS PRICE TARGET TO 2400 (3800) PENCE - 'BUY'

----------

JEFFERIES CUTS BRITISH AMERICAN TOBACCO PRICE TARGET TO 4800 (4900) PENCE - 'BUY'

----------

CREDIT SUISSE CUTS RECKITT-BENCKISER-PRICE TARGET TO 5550 (5800) PENCE - UNDERPERFORM

----------

CREDIT SUISSE CUTS SMITH & NEPHEW PRICE TARGET TO 1725 (1770) PENCE - 'NEUTRAL'

----------

FTSE 250

----------

LIBERUM RAISES PETS AT HOME TO 'BUY' ('HOLD')

----------

UBS CUTS ELEMENTIS PRICE TARGET TO 175 (185) PENCE - 'BUY'

----------

DEUTSCHE BANK RAISES CAPITA GROUP PRICE TARGET TO 140 (120) PENCE - 'HOLD'

----------

BARCLAYS RAISES WORKSPACE GROUP PRICE TARGET TO 1000 (980) PENCE - 'OVERWEIGHT'

----------

BARCLAYS RAISES DERWENT LONDON PRICE TARGET TO 3100 (3000) PENCE - 'UNDERWEIGHT'

----------

BARCLAYS CUTS BBA AVIATION PRICE TARGET TO 347 (350) PENCE - 'OVERWEIGHT'

----------

BERENBERG RAISES FUTURE PRICE TARGET TO 1755 (1530) PENCE - 'BUY'

----------

BERENBERG CUTS MAN GROUP PRICE TARGET TO 192 (206) PENCE - 'BUY'

----------

BERENBERG CUTS BOVIS HOMES PRICE TARGET TO 1220 (1230) PENCE - 'BUY'

----------

JPMORGAN RAISES TRAVIS PERKINS PRICE TARGET TO 1400 (1356) PENCE - 'NEUTRAL'

----------

JEFFERIES CUTS WEIR GROUP PRICE TARGET TO 1395 (1440) PENCE - 'HOLD'

----------

OTHER MAIN MARKET AND AIM

----------

LIBERUM CUTS LOOKERS TO 'HOLD' ('BUY') - TARGET 30 (68) PENCE

----------

BERENBERG RAISES CHEMRING GROUP PRICE TARGET TO 200 (190) PENCE - 'HOLD

----------

BERENBERG RAISES TEAM17 PRICE TARGET TO 375 (330) PENCE - 'BUY'

----------

JPMORGAN CUTS FEVERTREE DRINKS PRICE TARGET TO 2400 (2740) PENCE - 'OVERWEIGHT'

----------

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.